PPI-668

· Presidio Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for PPI-668, covering 2012-11-16 to 2016-04-07. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 [Phase 2, Phase 3]

See pricing